Generate Biomedicines, Inc. (GENB)
NASDAQ:GENB
Want to see GENB full AI Analyst Report?
GENB Stock Chart & Stats
$12.45
--
Market closed
$12.45
--
Day’s Range― - ―
52-Week Range$11.00 - $16.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.98B
Enterprise Value$1.72B
Total Cash (Recent Filing)$516.64M
Total Debt (Recent Filing)$65.57M
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,192,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue238.77
Enterprise Value/Gross Profit436.57
Enterprise Value/Ebitda-28.35
Forecast
1Y Price Target
$25.40Price Target Upside104.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line GrowthSustained revenue increase indicates improving commercialization or partner revenue traction. Persistent top-line growth, if maintained, helps validate the platform, supports future scale-up, and can reduce reliance on external funding over the medium term.
AI-driven PlatformA machine-learning protein-engineering platform is a durable competitive asset: it enables repeated discovery across programs, supports faster candidate generation, and creates optionality for licensing and partnerships, lowering program-specific binary risk over time.
Moderate Nominal DebtRelatively modest absolute debt and year-over-year reduction limit near-term interest burden and covenant pressure. This preserves some financing flexibility versus high-debt peers and eases pressure on cashflows while the company pursues partnerships or additional capital.
Bears Say
Large, Worsening Cash BurnSevere and increasing cash outflows mean the business consumes significant liquidity each period. With free cash flow tracking net losses ~1.02x, cash burn is real and persistent, forcing recurring financing needs that can dilute shareholders and constrain strategic options.
Deeply Negative Equity And Shrinking AssetsA large negative equity position and material asset decline reflect accumulated losses and reduced balance-sheet flexibility. This limits access to traditional financing, weakens collateral for secured lending, and raises structural solvency and covenant concerns for future funding.
Very Weak ProfitabilityExtremely negative margins and widening losses show operating costs far exceed revenues. Without substantial revenue acceleration or cost restructuring, the firm lacks an internal path to break-even, increasing likelihood of external financing and dilution over the medium term.
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $16.79 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Generate Biomedicines, Inc.’s market cap is $1.98B.
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 128,192,490 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generate Biomedicines, Inc. Stock Smart Score
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
GENB Stock 12 Month Forecast
Average Price Target
$25.40
▲(104.02% Upside)
Ownership Overview
52.07% Insiders
5.30% Other Institutional Investors
42.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---